Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 4/20 | 0.39 |
| ▸ | MPO | P05164 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16313509 | 0.85 | AR (0.45) | SLC22A12ARMAOAMAOBDPP4 | |
| SCHEMBL8415471 | 0.84 | AR (0.39) | SLC22A12ARMAOAMAOBDPP4 | |
| SCHEMBL14039187 | 0.82 | MAOA (0.42) | SLC22A12ARMAOAMAOBDPP4 | |
| SCHEMBL551615 | 0.81 | SLC6A4 (0.45) | — | |
| SCHEMBL13041692 | 0.81 | HTR2A (0.47) | MAOAMAOBMPOIDH1KCNH2 | |
| SCHEMBL3751942 | 0.80 | KDM4E (0.43) | SLC22A12ARMAOAMAOBMPO | |
| SCHEMBL19437202 | 0.80 | MAOA (0.41) | SLC22A12ARMAOAMAOBDPP4 | |
| SCHEMBL305457 | 0.80 | MAOA (0.41) | ARMAOAMAOBDPP4MPO | |
| SCHEMBL22904292 | 0.80 | MAOA (0.41) | ARMAOAMAOBDPP4MPO | |
| SCHEMBL8236340 | 0.80 | MAOA (0.41) | SLC22A12ARMAOAMAOBDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107698560-A | One koji Ge Lieting preparation method | 石家庄度恩医药科技有限公司 | 2018-02-16 | — | — | CN | claimed |
| US-20230357279-A1 | SPIROCYCLIC COMPOUNDS | ASTRAZENECA AB (SE) | 2023-11-09 | — | — | US | disclosed |
| WO-2023125792-A1 | MULTI-SUBSTITUTED URACIL DERIVATIVE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 杭州奥默医药股份有限公司 | 2023-07-06 | — | — | WO | disclosed |
| WO-2021226208-A2 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| CN-109668988-A | A method of 2- (two bromomethyls) -4- fluorobenzonitrile in analysis measurement amber love song Ge Lieting | 浙江华贝药业有限责任公司 | 2019-04-23 | — | — | CN | disclosed |
| CN-108368090-A | Compounds as Immunomodulators | 百时美施贵宝公司 | 2018-08-03 | — | — | CN | disclosed |
| CN-108017614-A | DPP-4 inhibitor and its application in treatment diabetes B medicine is prepared | 中国科学院海洋研究所 | 2018-05-11 | — | — | CN | disclosed |
| CN-107698560-A | One koji Ge Lieting preparation method | 石家庄度恩医药科技有限公司 | 2018-02-16 | — | — | CN | disclosed |
| CN-107250126-A | Long-acting dipeptidyl peptidase-IV inhibitor, application and preparation method thereof | 四川科伦博泰生物医药股份有限公司 | 2017-10-13 | — | — | CN | disclosed |
| CN-103848811-B | Uracil derivant, its preparation method and application thereof | 齐鲁制药有限公司 | 2016-12-21 | — | — | CN | disclosed |
| EP-1829877-A1 | BICYCLIC PYRROLE DERIVATIVES | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2007-09-05 | — | — | EP | disclosed |
| WO-2007071738-A1 | CONDENSED HETEROCYCLIC COMPOUNDS USEFUL AS DPP-IV INHIBITORS | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007039178-A2 | PHENYL-[1,2,4]-OXADIAZOL-5-ONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039178-A2 | PHENYL-[1,2,4]-OXADIAZOL-5-ONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039172-A1 | PHENYL- AND PYRIDYL-I, 2 , 4 -OXADIAZOLONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
| US-20050010045-A1 | Reacting morpholine compound with a substituted benzene compound | TIAN WEI (SE) | 2005-01-13 | — | — | US | disclosed |
| US-6689882-B2 | REACTING A MORPHOLINE WITH A SUBSTITUTED BENZENE, WHEREIN MORPHOLINE IS USED AS A REACTANT AND AS THE ONLY ONE SOLVENT | ASTRAZENECA AB (SE) | 2004-02-10 | — | — | US | disclosed |
| US-20030171581-A1 | Process for the synthesis of morpholinylbenzenes | ASTRAZENECA AB (SE) | 2003-09-11 | — | — | US | disclosed |
| EP-1286977-A1 | A NEW PROCESS FOR THE SYNTHESIS OF MORPHOLINYLBENZENES | AstraZeneca AB (SE) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001087865-A1 | A NEW PROCESS FOR THE SYNTHESIS OF MORPHOLINYLBENZENES | ASTRAZENECA AB (SE) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171581-A1 | Process for the synthesis of morpholinylbenzenes | CYP1B1, TBCB, MAP1B | SLC22A12 4042/4885AR 3231/4885MAOA 327/4885 |
| US-20050010045-A1 | Reacting morpholine compound with a substituted benzene compound | CYP1B1, MYB, MYBBP1A | SLC22A12 4048/4885AR 1653/4885MAOA 206/4885 |
| US-20230357279-A1 | SPIROCYCLIC COMPOUNDS | PKD1, PKD2, CCNI | SLC22A12 1499/4885AR 50/4885MAOA 3883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.